Objective
The dysregulation of cell signaling pathways that mediate proliferation, survival, and migration is an underlying cause of many cancers. Dysregulation and over-expression of the Tie2 tyrosine kinase receptor, in particular, correlates to a poor prognosis for many human tumors, making Tie2 an attractive target for therapeutic intervention. Currently no FDA-approved therapeutics targeting the Tie2 receptor exist, and only a few candidate molecules are in early stage clinical trials. Moreover, development of Tie2-targeted molecular imaging agents for non-invasive visualization of Tie2 expression in vivo has been extremely limited compared to other cancer targets. Such imaging agents could help identify the best patient candidates for Tie2-targeted anti cancer therapies.
Although ligand-based antagonists have opened up new research directions for generating new cancer biologics, limitations in ligand binding affinity, expression yield, and stability have prevented all but a few from advancing to clinical trials. The limited success of ligand-based antagonists motivates me to use modified Tie2-receptor agonists, i.e. angiopoietins, as a starting point from which to develop ligand-based antagonists. Angiopoietin antagonists will be created by introducing mutations into an angiopoietin that retains Tie2 binding but that prevents ligand multimerization and receptor dimerization and activation. Yeast-displayed angiopoietin mutant libraries will then be created and screened by high-throughput flow cytometric sorting to identify variants with increased expression and stability and affinity to Tie2.
We will perform pre-clinical studies on the high affinity angiopoietin variants to determine their potential as in vivo molecular imaging agents and cancer therapeutics. In addition, we will fully characterize the binding and biological properties of the variants in both cell culture and pre-clinical solid and metastatic tumor models.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences cell biology cell signaling
- natural sciences biological sciences genetics mutation
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2011-CIG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MC-CIG - Support for training and career development of researcher (CIG)
Coordinator
84105 Beer Sheva
Israel
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.